^(125)I抗AFP抗体在肝癌病人体内的药代动力学观察  

A PHARMACOKINETIC STUDY OF^(125)I-LABLED ANTI-AFP ANTIBODY IN PATIENTS WITH PRIMARY LIVER CANCER

作　　者：刘志辉[1] 吴英德[1] 胡晓桦[1] 周德南[1] 宋向群[1] 

机构地区：[1]广西医科大学附属肿瘤医院,南宁530021

出　　处：《广西医科大学学报》2000年第4期622-625,共4页Journal of Guangxi Medical University

摘　　要：目的 :用 1 2 5 I标记抗 AFP多克隆抗体治疗 12例原发性肝癌患者 ,观察其药代动力学特征。方法 :用改良氯胺 - T法制备 1 2 5 I-抗 AFP抗体 ,标记率为 6 5 %～ 83% ,比放射性为 5 5 .5～ 74MBq/ m g (Ig G)。全部病例采用 Seldinger插管技术 ,经肝动脉注射给药。给药后在不同时间点采集外周静脉血测放射活性。所得数据用计算机程序 PK - GRAPH模拟出 1 2 5 I-抗 AFP抗体的药代动力学模型、血放射性 -时间曲线和计算出各种动力学参数。结果 :全组病例的药代动力学模式为二室模型 ;t1 /2α为 (1.85± 1.79) h,t1 /2β为 (15 6 .46± 6 5 .11) h。血清 AFP>40 0μg/ L和 AFP阴性病人药动学参数无显著性差异 ,不同的抗体用量以及是否经肝动脉用碘油抗癌药乳剂作 TAE对药动学参数均无显著性影响 (P >0 .0 5 )。结论 :1 2 5 I-抗 AFP抗体经肝动脉给药 ,在肝癌病人体内有较长的清除半衰期。Objective:To study the pharmacokinetic of 125 I labled anti human AFP antibody( 125 I anti AFP)radioimmunotherapy in 12 patients with primary liver cancer(PLC)by nuclide tracing Methods:Using modified chloamin T method produce isotopic 125 I anti AFPAb which was administered via hepatic artery integrated with transcatheter arterial chemoembolization(TACE)(n=5)and/or trasarterial infusion(TAI)(n=7) by Seldinger technique The radioactivity measurement of blood sample was taken in different time spots after infusion of 125 I anti AFPAb The data was analyzed by using a computer program of PK GRAPH Results:The microcomputer graphic portrayal met a two compartment for all patients The model shows the half life time of a phase(t 1/2α ),a rapidly decreasing component,was short,and the t 1/2 of β phase,clearance half life time,was longer in the slow component The mean value of T1/2a and t 1/2β (±s)was (1 85±1 79)hr,(156 46±65 11)hr,respectively The value of t 1/2β was not statistically different in those patients whose plasma AFP level was>400 μg/L and negative,antibody dose was 3 mg and 5 mg,and combining with TAE or TAI Conclusion:The results suggest that the pharmacokinetic of 125 I anti AFPAb would not be influenced by such factor as plasma AFP level and the antibody dose In addition,the t 1/2β was long,which would be benifitial for tumor to uptake more 125 I anti AFPAb and perhaps more number of hepatocellular carcinoma cells would be killed

关 键 词：肝肿瘤 ^125I 抗甲胎蛋白抗体 药代动力学 

分 类 号：R735.7[医药卫生—肿瘤] R969.1[医药卫生—临床医学]